Acute myeloid leukaemia
Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The past decade has witnessed an increasingly improved scientific understanding of the underlying biology of acute myeloid leukaemia, leading to enhanced prognostication tools and refined risk assessments, and most...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 2023-06, Vol.401 (10393), p.2073-2086 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2086 |
|---|---|
| container_issue | 10393 |
| container_start_page | 2073 |
| container_title | The Lancet (British edition) |
| container_volume | 401 |
| creator | DiNardo, Courtney D Erba, Harry P Freeman, Sylvie D Wei, Andrew H |
| description | Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The past decade has witnessed an increasingly improved scientific understanding of the underlying biology of acute myeloid leukaemia, leading to enhanced prognostication tools and refined risk assessments, and most especially incorporating measurable residual disease (MRD) into longitudinal risk assessments. The classification of acute myeloid leukaemia has recently been updated by WHO and the International Consensus Classification (ICC). Recommendations for prognostic stratification, response assessment, and MRD determination have also been updated by the European LeukemiaNet. Treatment options have evolved substantially in the last 5 years for patients with newly diagnosed acute myeloid leukaemia, leading to improved outcomes in intensively treated patients and those more appropriate for non-intensive chemotherapy. More effective targeted treatment options in the relapsed setting are also available, further advancing the treatment armamentarium and improving patient outcomes. |
| doi_str_mv | 10.1016/S0140-6736(23)00108-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2802884021</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673623001083</els_id><sourcerecordid>2826185642</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-5e6b5bc70a78a41ed156f3c12a54b1cacd629a75cd5c82fd2347d22d62a2f973</originalsourceid><addsrcrecordid>eNqFkD1LA0EQhhdRTIzWVkrAJhans9-bSkLwCwIWprBb9nbn4OJdLt7eCfn3Xj5MYWM1MDzvO8NDyBWFOwpU3b8DFZAozdWI8VsACibhR6RPhRaJFPrjmPQPSI-cxbgAAKFAnpIe16CMBNknlxPfNjgs11hUeRgW2H46LHN3Tk4yV0S82M8BmT89zqcvyezt-XU6mSVejFmTSFSpTL0Gp40TFAOVKuOeMidFSr3zQbGx09IH6Q3LAuNCB8a6rWPZWPMBGe1qV3X11WJsbJlHj0Xhlli10TIDzBgBjHbozR90UbX1snuuo5iiRirBOkruKF9XMdaY2VWdl65eWwp2I85uxdmNFcu43YqzvMtd79vbtMRwSP2a6oCHHYCdje8caxt9jkuPIa_RNzZU-T8nfgBRlXos</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2826185642</pqid></control><display><type>article</type><title>Acute myeloid leukaemia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>DiNardo, Courtney D ; Erba, Harry P ; Freeman, Sylvie D ; Wei, Andrew H</creator><creatorcontrib>DiNardo, Courtney D ; Erba, Harry P ; Freeman, Sylvie D ; Wei, Andrew H</creatorcontrib><description>Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The past decade has witnessed an increasingly improved scientific understanding of the underlying biology of acute myeloid leukaemia, leading to enhanced prognostication tools and refined risk assessments, and most especially incorporating measurable residual disease (MRD) into longitudinal risk assessments. The classification of acute myeloid leukaemia has recently been updated by WHO and the International Consensus Classification (ICC). Recommendations for prognostic stratification, response assessment, and MRD determination have also been updated by the European LeukemiaNet. Treatment options have evolved substantially in the last 5 years for patients with newly diagnosed acute myeloid leukaemia, leading to improved outcomes in intensively treated patients and those more appropriate for non-intensive chemotherapy. More effective targeted treatment options in the relapsed setting are also available, further advancing the treatment armamentarium and improving patient outcomes.</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(23)00108-3</identifier><identifier>PMID: 37068505</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Acute myeloid leukemia ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bone marrow ; Chemotherapy ; Classification ; Diagnostic tests ; Flow cytometry ; Hematology ; Humans ; Leukemia ; Leukemia, Myeloid, Acute - diagnosis ; Leukemia, Myeloid, Acute - drug therapy ; Medical diagnosis ; Medical prognosis ; Morphology ; Mutation ; Neoplasm, Residual - diagnosis ; Neoplasm, Residual - drug therapy ; Neoplasm, Residual - etiology ; Prognosis ; Risk Assessment ; Treatment Outcome ; Uranium</subject><ispartof>The Lancet (British edition), 2023-06, Vol.401 (10393), p.2073-2086</ispartof><rights>2023 Elsevier Ltd</rights><rights>Copyright © 2023 Elsevier Ltd. All rights reserved.</rights><rights>2023. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c492t-5e6b5bc70a78a41ed156f3c12a54b1cacd629a75cd5c82fd2347d22d62a2f973</citedby><cites>FETCH-LOGICAL-c492t-5e6b5bc70a78a41ed156f3c12a54b1cacd629a75cd5c82fd2347d22d62a2f973</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0140673623001083$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37068505$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DiNardo, Courtney D</creatorcontrib><creatorcontrib>Erba, Harry P</creatorcontrib><creatorcontrib>Freeman, Sylvie D</creatorcontrib><creatorcontrib>Wei, Andrew H</creatorcontrib><title>Acute myeloid leukaemia</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The past decade has witnessed an increasingly improved scientific understanding of the underlying biology of acute myeloid leukaemia, leading to enhanced prognostication tools and refined risk assessments, and most especially incorporating measurable residual disease (MRD) into longitudinal risk assessments. The classification of acute myeloid leukaemia has recently been updated by WHO and the International Consensus Classification (ICC). Recommendations for prognostic stratification, response assessment, and MRD determination have also been updated by the European LeukemiaNet. Treatment options have evolved substantially in the last 5 years for patients with newly diagnosed acute myeloid leukaemia, leading to improved outcomes in intensively treated patients and those more appropriate for non-intensive chemotherapy. More effective targeted treatment options in the relapsed setting are also available, further advancing the treatment armamentarium and improving patient outcomes.</description><subject>Acute myeloid leukemia</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bone marrow</subject><subject>Chemotherapy</subject><subject>Classification</subject><subject>Diagnostic tests</subject><subject>Flow cytometry</subject><subject>Hematology</subject><subject>Humans</subject><subject>Leukemia</subject><subject>Leukemia, Myeloid, Acute - diagnosis</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Medical diagnosis</subject><subject>Medical prognosis</subject><subject>Morphology</subject><subject>Mutation</subject><subject>Neoplasm, Residual - diagnosis</subject><subject>Neoplasm, Residual - drug therapy</subject><subject>Neoplasm, Residual - etiology</subject><subject>Prognosis</subject><subject>Risk Assessment</subject><subject>Treatment Outcome</subject><subject>Uranium</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkD1LA0EQhhdRTIzWVkrAJhans9-bSkLwCwIWprBb9nbn4OJdLt7eCfn3Xj5MYWM1MDzvO8NDyBWFOwpU3b8DFZAozdWI8VsACibhR6RPhRaJFPrjmPQPSI-cxbgAAKFAnpIe16CMBNknlxPfNjgs11hUeRgW2H46LHN3Tk4yV0S82M8BmT89zqcvyezt-XU6mSVejFmTSFSpTL0Gp40TFAOVKuOeMidFSr3zQbGx09IH6Q3LAuNCB8a6rWPZWPMBGe1qV3X11WJsbJlHj0Xhlli10TIDzBgBjHbozR90UbX1snuuo5iiRirBOkruKF9XMdaY2VWdl65eWwp2I85uxdmNFcu43YqzvMtd79vbtMRwSP2a6oCHHYCdje8caxt9jkuPIa_RNzZU-T8nfgBRlXos</recordid><startdate>20230617</startdate><enddate>20230617</enddate><creator>DiNardo, Courtney D</creator><creator>Erba, Harry P</creator><creator>Freeman, Sylvie D</creator><creator>Wei, Andrew H</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20230617</creationdate><title>Acute myeloid leukaemia</title><author>DiNardo, Courtney D ; Erba, Harry P ; Freeman, Sylvie D ; Wei, Andrew H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-5e6b5bc70a78a41ed156f3c12a54b1cacd629a75cd5c82fd2347d22d62a2f973</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acute myeloid leukemia</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bone marrow</topic><topic>Chemotherapy</topic><topic>Classification</topic><topic>Diagnostic tests</topic><topic>Flow cytometry</topic><topic>Hematology</topic><topic>Humans</topic><topic>Leukemia</topic><topic>Leukemia, Myeloid, Acute - diagnosis</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Medical diagnosis</topic><topic>Medical prognosis</topic><topic>Morphology</topic><topic>Mutation</topic><topic>Neoplasm, Residual - diagnosis</topic><topic>Neoplasm, Residual - drug therapy</topic><topic>Neoplasm, Residual - etiology</topic><topic>Prognosis</topic><topic>Risk Assessment</topic><topic>Treatment Outcome</topic><topic>Uranium</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DiNardo, Courtney D</creatorcontrib><creatorcontrib>Erba, Harry P</creatorcontrib><creatorcontrib>Freeman, Sylvie D</creatorcontrib><creatorcontrib>Wei, Andrew H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News & ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DiNardo, Courtney D</au><au>Erba, Harry P</au><au>Freeman, Sylvie D</au><au>Wei, Andrew H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acute myeloid leukaemia</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2023-06-17</date><risdate>2023</risdate><volume>401</volume><issue>10393</issue><spage>2073</spage><epage>2086</epage><pages>2073-2086</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><abstract>Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The past decade has witnessed an increasingly improved scientific understanding of the underlying biology of acute myeloid leukaemia, leading to enhanced prognostication tools and refined risk assessments, and most especially incorporating measurable residual disease (MRD) into longitudinal risk assessments. The classification of acute myeloid leukaemia has recently been updated by WHO and the International Consensus Classification (ICC). Recommendations for prognostic stratification, response assessment, and MRD determination have also been updated by the European LeukemiaNet. Treatment options have evolved substantially in the last 5 years for patients with newly diagnosed acute myeloid leukaemia, leading to improved outcomes in intensively treated patients and those more appropriate for non-intensive chemotherapy. More effective targeted treatment options in the relapsed setting are also available, further advancing the treatment armamentarium and improving patient outcomes.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>37068505</pmid><doi>10.1016/S0140-6736(23)00108-3</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 2023-06, Vol.401 (10393), p.2073-2086 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2802884021 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Acute myeloid leukemia Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bone marrow Chemotherapy Classification Diagnostic tests Flow cytometry Hematology Humans Leukemia Leukemia, Myeloid, Acute - diagnosis Leukemia, Myeloid, Acute - drug therapy Medical diagnosis Medical prognosis Morphology Mutation Neoplasm, Residual - diagnosis Neoplasm, Residual - drug therapy Neoplasm, Residual - etiology Prognosis Risk Assessment Treatment Outcome Uranium |
| title | Acute myeloid leukaemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T12%3A43%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acute%20myeloid%20leukaemia&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=DiNardo,%20Courtney%20D&rft.date=2023-06-17&rft.volume=401&rft.issue=10393&rft.spage=2073&rft.epage=2086&rft.pages=2073-2086&rft.issn=0140-6736&rft.eissn=1474-547X&rft_id=info:doi/10.1016/S0140-6736(23)00108-3&rft_dat=%3Cproquest_cross%3E2826185642%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2826185642&rft_id=info:pmid/37068505&rft_els_id=S0140673623001083&rfr_iscdi=true |